Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

SALT LAKE CITY, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences.

• The Wells Fargo Healthcare Conference with a fireside chat on Thursday, Sept. 4 at 3:45pm ET.
• The Morgan Stanley Annual Global Healthcare Conference with a fireside chat on Wednesday, Sept. 10 at 7:45am ET.

Links to the live and archived webcasts of both presentations can be viewed at investor.myriad.com.

About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Investor Contact 
Matt Scalo 
(801) 584-3532 
[email protected] 

Media Contact 
Kate Schraml
(224) 875-4493 
[email protected]

You May Also Be Interested In

• Exor Press Release - Periodic Report on the Buyback Program
• Embedded Finance Revenue to Reach $617 Billion Globally by 2031, as B2B Revenue Surges 390%
• Share repurchase programme: Transactions of week 39 2026